Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-08
2011-03-08
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07902163
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
REFERENCES:
patent: 5536638 (1996-07-01), Rossau et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5843641 (1998-12-01), Brown et al.
patent: 5849290 (1998-12-01), Brown et al.
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6077833 (2000-06-01), Bennett et al.
patent: 6194150 (2001-02-01), Stinchcomb et al.
patent: 6352829 (2002-03-01), Chenchik et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6784290 (2004-08-01), Monia et al.
patent: 7132530 (2006-11-01), Bennett et al.
patent: 7622455 (2009-11-01), Bennett et al.
patent: 7678895 (2010-03-01), Bennett et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0156040 (2002-10-01), Oberley et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0091919 (2004-05-01), Bennett et al.
patent: 2005/0019915 (2005-01-01), Bennett et al.
patent: 2006/0229268 (2006-10-01), Benjamin et al.
patent: 2006/0293269 (2006-12-01), Bennett et al.
patent: 2007/0054869 (2007-03-01), Bennett et al.
patent: 2007/0117772 (2007-05-01), Bennett et al.
patent: WO 90/05181 (1990-05-01), None
patent: WO 94/19493 (1994-09-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 97/31012 (1997-08-01), None
patent: WO 02/03979 (2002-01-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/000707 (2003-01-01), None
patent: WO 03/004602 (2003-01-01), None
patent: WO 2005/040180 (2005-06-01), None
Klug et al. Pflugers Archiv: European Journal of Physiology, 2001 vol. 441, Suppl 6, p. R205. Abstract No. P20-7.
Smith et al. Journal of Clinical Investigation, 2006 vol. 116:2290-2296.
Kagiyama et al. (Brain Research, 1999 vol. 829:120-124).
Sinnayah et al. (Molecular Brain Research, 1997 vol. 50:43-50).
Dean et al. Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 2003 vol. 22:9087-9096.
Hammond, S. M. et al., “Post-Transcriptional Gene Silencing by Double-Stranded RNA,”Nature(2002) 2:110-119.
PCT International Search Report for PCT/US2004/031673 dated Aug. 22, 2005.
Agrawal, S., et al., “Antisense therapeutics: is it as simple as complementary base recognition?,”Mol. Medicine Today(2000) 6:72-81.
Al-Chalabi, A. et al., “Recent advances in amyotrophic lateral sclerosis,”Curr Opin Neurol. (2000) 13(4):397-405.
Alisky, J.M. et al., “Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases,”Hum Gene Ther. (2000) 11(17):2315-29.
Berger, I., et al., “Crystal structures of B-DNA with incorporated 2′-deoxy-2′-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability,”Nucleic Acids Res. (1998) 15;26(10):2473-80.
Berger, M. et al., “Universal bases for hybridization, replication and chain termination,” Nucleic Acids Research (2000) 28(15): 2911-2914.
Branch, A. D., “A good antisense molecule is hard to find,”TIBS(1998) 23:45-50.
Brooks, B.R. et al., “El Escorial revisited: Revisited criteria for the diagnosis of amyotrophic lateral sclerosis,”ALS and Other Motor Neuron Disorders(2000) 1:293-299.
Bruijn, L. I., et al., “Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1,”Science(1998) 281(5384):1851-4.
Cleveland, D. W., et al., “Oxidation versus aggregation—how do SOD1 mutants cause ALS?”Nat Med. (2000) 6(12):1320-1.
Crooke, S.T., “Basic Principles of Antisense Therapeutics,” (1998), Chapter 1, Springer-Verlag, New York.
Fridovich, I., “Superoxide radical and superoxide dismutases,”Annu. Rev. Biochem. (1995) 64:97-112.
Green, D. W., et al, “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,”J Am Coll Surg. (2000) 191(1):93-105.
Grzanna, R., et al, “Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects,”Mol Brain Res. (1998) 63(1):35-52.
Gulesserian, T., et al., “Superoxide Dimutase SOD 1, Encoded on Chromosome 21, but Not SOD2 Is Overexpressed in Brains of Patients With Down Syndrome,”J. Investig Med. (2001) 49(1):41-6.
Hottinger, A. F., “The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis,”Eur J Neurosci. (1997) 9(7):1548-51.
Huang, P. et al., “Superoxide dismutase as a target for the selective killing of cancer cells,”Nature. (2000) 407(6802):390-5.
Jen, K. Y., et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,”Stem Cells(2000) 18:307-19.
Kawata, A., et al., “Aberrant splicing of human Cu/Zn superoxide dimutase (SOD1) RNA transcripts,”Neuroreport. (2000) 11(12):2649-53.
Klivenyi, P., et al., “Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis,”Nat Med. (1999) 5(3):347-50.
Lee, W. G., et al., “Molecular Cloning and High-Level Expression of Human Cytoplasmic Superoxide Dismutase Gene inEscherichia coli,” Kor. Jour. Microbiol. (1990) 28(2): 91-7.
Milner, N., et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays,”Nature Biotechnology(1997) 15:537-41.
Misra, A., et al, “Drug delivery to the central nervous system: a review,”J Pharm Pharmaceut Sci(2003) 6(2):252-273.
Muramatsu, H., et al., “Superoxide Dismutase in SAS Human Tongue Carcinoma Cell Line Is a Factor Defining Invasiveness and Cell Motility,”Cancer Research(1995) 55:6210-4.
Rothstein, J. D., et al, “Chronic inhibition of superoxide dismutase produces apoptotic death of spinal Neurons”Proc Natl Acad Sci U S A. (1994) 91(10):4155-9.
Rowland, L. P., “Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999,”J. Neurol. Sci. (2000) 180:2-6.
Sanghvi, Y.S., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides, ”Antisense Research and Applications(1993) CRC Press, Boca Raton, pp. 276-278.
Skerra, A., “Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity,”Nucleic Acids Research(1992) 20(14):3551-4.
Trotti, D., et al., “SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter,” Nat Neurosci. (1999) 2(5):427-33.
Troy, C. M., et al., “Down-regulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway,”J Neurosci. (1996) 16(1):253-61.
Troy, C. M., et al., “Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells,”Proc Natl Acad Sci U S A. (1994) 91(14):6384-7.
Non-final Office Action from U.S. Appl. No. 10/672,866, mail date May 3, 2005.
Non-final Office Action from U.S. Appl. No. 09/888,360, mail date May 21, 2002.
Final Rejection from U.S. Appl. No. 09/888,360, mail date Feb. 11, 2003.
Non-final Office Action from U.S. Appl. No. 10/633,843, mail date Nov. 15, 2005.
Final Rejection from U.S. Appl. No. 10/633,843, mail date Apr. 5, 2006.
Notice of Allowance from U.S. Appl. No. 10/633,843, mail date Jul. 3, 2006.
Non-final Office Action from U.S. Appl. No. 11/449,207, mail date Feb. 12, 2007.
Final Office Act
Bennett C. Frank
Dobie Kenneth W.
Freier Susan M.
Gibbs Terra Cotta
ISIS Pharmaceuticals Inc.
Jones Day
McGarry Sean
LandOfFree
Antisense modulation of superoxide dismutase 1, soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of superoxide dismutase 1, soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of superoxide dismutase 1, soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706393